[Cholesterol and vascular disease. Study of pravastatin ].
Variations in lipid profile and incidence of vascular events were evaluated. Group 1 had a 29.3% reduction of total and a 38.3% reduction of LDL cholesterol as against reductions of 9% and 9.6% respectively in group 2. No significant difference was observed between the two groups as far as the vascular events considered were concerned. Pravastatin is an effective and safe drug. The lack of influence on the evolution of vascular disease would appear to be correlated to the small number of subjects studied and the short follow-up.
Bellandi
F
F
II Divisione di Medicina, Ospedale di Prato.
Cantini
F
F
Pedone
T
T
Palchetti
R
R
D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000517:prevention & control*; D003327:Coronary Disease / Q000517:prevention & control*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*
D008077:Lipoproteins, LDL; D017035:Pravastatin
Colesterolo e patologia vascolare. Studio con pravastatina.